Josh Wolfe is a co-founder and the managing partner at Lux Capital, a venture capital fund that invests in deep technology and frontier science. He serves on the boards of Aera Therapeutics, Cajal Neuroscience, Eikon Therapeutics, Impulse Labs, Kallyope, Osmo, and Variant Bio, and led investments in Anduril, Planet, Echodyne, Hadrian, and Resilience. A Westinghouse semi-finalist and published scientist, Josh began his career at Salomon Smith Barney and Merrill Lynch. He edits the Forbes/Wolfe Emerging Tech Report and has advised the White House and Congress on emerging technologies. Josh is also a term member of the Council on Foreign Relations, Trustee of the Santa Fe Institute, and Chairman of Coney Island Prep. He holds a B.S. in Economics and Finance from Cornell.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related